JPH0737978B2 - 生育可能細胞の標識 - Google Patents

生育可能細胞の標識

Info

Publication number: JPH0737978B2
Authority: JP; Japan
Prior art keywords: cells; labeling; cell; dye; good
Prior art date: 1986-10-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP62277256A

Other languages

English (en)

Japanese (ja)

Other versions

JPS63122954A (ja

Inventor

ポール・カール・ホーラン

ブルース・デイビッド・ジェンセン

シュー・エレン・スレザック

Original Assignee

スミスクライン・ベックマン・コーポレイション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-10-31

Filing date

1987-10-30

Publication date

1995-04-26

1987-10-30 Application filed by スミスクライン・ベックマン・コーポレイション filed Critical スミスクライン・ベックマン・コーポレイション

1988-05-26 Publication of JPS63122954A publication Critical patent/JPS63122954A/ja

1995-04-26 Publication of JPH0737978B2 publication Critical patent/JPH0737978B2/ja

2010-04-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000002372 labelling Methods 0.000 title claims abstract description 35
210000004027 cell Anatomy 0.000 claims abstract description 124
238000000034 method Methods 0.000 claims abstract description 48
ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims abstract description 42
210000003743 erythrocyte Anatomy 0.000 claims abstract description 24
230000003833 cell viability Effects 0.000 claims abstract description 12
210000001772 blood platelet Anatomy 0.000 claims description 33
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
239000008103 glucose Substances 0.000 claims description 16
210000000170 cell membrane Anatomy 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 15
210000000265 leukocyte Anatomy 0.000 claims description 11
239000006173 Good's buffer Substances 0.000 claims description 10
230000000065 osmolyte Effects 0.000 claims description 10
235000000346 sugar Nutrition 0.000 claims description 9
150000005846 sugar alcohols Chemical class 0.000 claims description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
229930195725 Mannitol Natural products 0.000 claims description 8
150000001413 amino acids Chemical class 0.000 claims description 8
-1 di-substituted methylene Chemical group 0.000 claims description 8
239000000594 mannitol Substances 0.000 claims description 8
235000010355 mannitol Nutrition 0.000 claims description 8
230000003204 osmotic effect Effects 0.000 claims description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
238000005192 partition Methods 0.000 claims description 7
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
150000008163 sugars Chemical class 0.000 claims description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
239000011593 sulfur Chemical group 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 4
XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical group OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 claims description 3
OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical group OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 3
208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 3
238000013421 nuclear magnetic resonance imaging Methods 0.000 claims description 3
GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical group OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 claims description 2
239000006172 buffering agent Substances 0.000 claims 3
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
125000001424 substituent group Chemical group 0.000 claims 2
CLHYKAZPWIRRRD-UHFFFAOYSA-N 1-hydroxypropane-1-sulfonic acid Chemical compound CCC(O)S(O)(=O)=O CLHYKAZPWIRRRD-UHFFFAOYSA-N 0.000 claims 1
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims 1
HNUWDURNWORUHQ-UHFFFAOYSA-N 2-amino-5-hydroxy-4,4-bis(hydroxymethyl)pentane-2-sulfonic acid Chemical compound OCC(CC(S(=O)(=O)O)(N)C)(CO)CO HNUWDURNWORUHQ-UHFFFAOYSA-N 0.000 claims 1
PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 claims 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
239000000975 dye Substances 0.000 abstract description 93
230000000740 bleeding effect Effects 0.000 abstract description 4
230000012010 growth Effects 0.000 abstract description 3
238000010790 dilution Methods 0.000 abstract description 2
239000012895 dilution Substances 0.000 abstract description 2
210000004748 cultured cell Anatomy 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
230000036647 reaction Effects 0.000 abstract 1
238000010186 staining Methods 0.000 description 23
239000000243 solution Substances 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
229920005654 Sephadex Polymers 0.000 description 16
239000012507 Sephadex™ Substances 0.000 description 16
239000006228 supernatant Substances 0.000 description 16
150000001875 compounds Chemical class 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
235000002639 sodium chloride Nutrition 0.000 description 12
239000000725 suspension Substances 0.000 description 12
239000008188 pellet Substances 0.000 description 10
230000007423 decrease Effects 0.000 description 9
210000002381 plasma Anatomy 0.000 description 9
239000000523 sample Substances 0.000 description 9
238000005119 centrifugation Methods 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
239000012528 membrane Substances 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000012981 Hank's balanced salt solution Substances 0.000 description 6
102000001554 Hemoglobins Human genes 0.000 description 6
108010054147 Hemoglobins Proteins 0.000 description 6
125000001931 aliphatic group Chemical group 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000004743 Polypropylene Substances 0.000 description 5
239000006285 cell suspension Substances 0.000 description 5
229920001155 polypropylene Polymers 0.000 description 5
108010017384 Blood Proteins Proteins 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 4
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
210000001995 reticulocyte Anatomy 0.000 description 4
238000000926 separation method Methods 0.000 description 4
239000001509 sodium citrate Substances 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
206010018910 Haemolysis Diseases 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
230000002411 adverse Effects 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000298 carbocyanine Substances 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
230000008588 hemolysis Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000002002 slurry Substances 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000005284 excitation Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
229960005150 glycerol Drugs 0.000 description 2
238000005534 hematocrit Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
229960000367 inositol Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000003458 metachromatic effect Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
WVIICGIFSIBFOG-UHFFFAOYSA-N pyrylium Chemical compound C1=CC=[O+]C=C1 WVIICGIFSIBFOG-UHFFFAOYSA-N 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000012192 staining solution Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
FNPBHXSBDADRBT-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;iodide Chemical compound [I-].C[N+](C)(C)CCO FNPBHXSBDADRBT-UHFFFAOYSA-M 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
QARJWQSAAYUDJA-UHFFFAOYSA-N 3-(aminomethyl)-1,4-dihydroxy-3-(hydroxymethyl)-2-methylbutane-2-sulfonic acid Chemical compound OCC(C)(S(O)(=O)=O)C(CN)(CO)CO QARJWQSAAYUDJA-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
235000019743 Choline chloride Nutrition 0.000 description 1
101710112752 Cytotoxin Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
240000001398 Typha domingensis Species 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
230000000244 anti-pseudomonal effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000000981 basic dye Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
238000005298 biophysical measurement Methods 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
229960003178 choline chloride Drugs 0.000 description 1
210000000448 cultured tumor cell Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000005283 ground state Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100001160 nonlethal Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000001048 orange dye Substances 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000003133 propidium iodide exclusion Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000002165 resonance energy transfer Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
229940083599 sodium iodide Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
OSQUFVVXNRMSHL-LTHRDKTGSA-M sodium;3-[(2z)-2-[(e)-4-(1,3-dibutyl-4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-ylidene)but-2-enylidene]-1,3-benzoxazol-3-yl]propane-1-sulfonate Chemical compound [Na+].O=C1N(CCCC)C(=S)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 OSQUFVVXNRMSHL-LTHRDKTGSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000007447 staining method Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000012085 test solution Substances 0.000 description 1
239000008181 tonicity modifier Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

JP62277256A 1986-10-31 1987-10-30 生育可能細胞の標識 Expired - Lifetime JPH0737978B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US925192		1986-10-31
US06/925,192 US4783401A (en)	1986-10-31	1986-10-31	Viable cell labelling

Publications (2)

Publication Number	Publication Date
JPS63122954A JPS63122954A (ja)	1988-05-26
JPH0737978B2 true JPH0737978B2 (ja)	1995-04-26

Family

ID=25451357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62277256A Expired - Lifetime JPH0737978B2 (ja)	1986-10-31	1987-10-30	生育可能細胞の標識

Country Status (15)

Country	Link
US (1)	US4783401A (da)
EP (1)	EP0266194B1 (da)
JP (1)	JPH0737978B2 (da)
KR (1)	KR970000783B1 (da)
CN (1)	CN1014547B (da)
AT (1)	ATE110417T1 (da)
AU (1)	AU606894B2 (da)
CA (1)	CA1311685C (da)
DE (1)	DE3750421T2 (da)
DK (1)	DK175074B1 (da)
IE (1)	IE69533B1 (da)
IL (1)	IL84278A (da)
PH (1)	PH23564A (da)
PT (1)	PT86028B (da)
ZA (1)	ZA878157B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4859584A (en) *	1986-10-31	1989-08-22	Smithkline Beckman Corporation	Cell growth rate determination by measurement of changes in cyanine dye levels in plasma membranes
ATE145337T1 (de) *	1988-05-02	1996-12-15	Phanos Tech Inc	Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US5256532A (en) *	1988-05-02	1993-10-26	Zynaxis Technologies, Inc.	Methods, reagents and test kits for determination of subpopulations of biological entities
US4963478A (en) *	1988-07-05	1990-10-16	Immucor, Inc.	Article for preforming immunological assays utilizing organic dyes and method for producing and utilizing same
JPH02187661A (ja) *	1989-01-13	1990-07-23	J M L:Kk	網状赤血球の新染色法
US5169788A (en) *	1989-06-09	1992-12-08	New England Deaconess Hospital Corporation	Methods of measuring membrane potential using j-aggregate forming dyes
US5279936A (en) *	1989-12-22	1994-01-18	Syntex (U.S.A.) Inc.	Method of separation employing magnetic particles and second medium
US5375606A (en) *	1990-02-28	1994-12-27	Zynaxis, Inc.	Bio-analytical separation method
US5242792A (en) *	1991-02-25	1993-09-07	The United States Of America As Represented By The Secretary Of The Navy	Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
WO1993002360A1 (en) *	1991-07-16	1993-02-04	Transmed Biotech Incorporated	Methods and compositions for simultaneous analysis of multiple analytes
EP0643706A1 (en) *	1991-11-27	1995-03-22	Zynaxis Inc.	Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US5334509A (en) *	1992-10-22	1994-08-02	Riordan Neil H	Method for detecting intestinal pathogen dientamoeba fragilis
US5585246A (en) *	1993-02-17	1996-12-17	Biometric Imaging, Inc.	Method for preparing a sample in a scan capillary for immunofluorescent interrogation
AU6365894A (en) *	1993-03-16	1994-10-11	Alliance Pharmaceutical Corporation	Fluorocarbon compositions containing a visible or fluorescent label
ES2156927T3 (es) *	1994-10-20	2001-08-01	Sysmex Corp	Reactivo y metodo para analizar componentes solidos en orina.
US6004536A (en) *	1995-11-14	1999-12-21	Molecular Probes, Inc.	Lipophilic cyanine dyes with enchanced aqueous solubilty
US5804389A (en) *	1995-12-29	1998-09-08	Phanos Technologies, Inc.	Method for detecting abnormal epithelial cell shedding
US5989835A (en) *	1997-02-27	1999-11-23	Cellomics, Inc.	System for cell-based screening
US6008010A (en) *	1996-11-01	1999-12-28	University Of Pittsburgh	Method and apparatus for holding cells
US6727071B1 (en)	1997-02-27	2004-04-27	Cellomics, Inc.	System for cell-based screening
US7117098B1 (en)	1997-02-27	2006-10-03	Cellomics, Inc.	Machine-readable storage medium for analyzing distribution of macromolecules between the cell membrane and the cell cytoplasm
CA2282658C (en)	1997-02-27	2003-02-25	Cellomics, Inc.	A system for cell-based screening
US6858439B1 (en) *	1999-03-15	2005-02-22	Aviva Biosciences	Compositions and methods for separation of moieties on chips
EP1163372A4 (en) *	1999-03-24	2002-10-02	Princeton Separations	CHEMICALLY REACTIVE CYANINE DYES AND DERIVATIVES IN A LEVEL
US6986993B1 (en) *	1999-08-05	2006-01-17	Cellomics, Inc.	System for cell-based screening
WO2001042786A2 (en)	1999-12-09	2001-06-14	Cellomics, Inc.	System for cell based screening : cell spreading
US20090087450A1 (en) *	2000-01-11	2009-04-02	Greenville Hospital System	Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
DK1248836T3 (da)	2000-01-11	2005-08-15	Greenville Hospital System	Fremgangsmåde til fremstilling af vacciner ved anvendelse af hybridceller
US20070212338A1 (en) *	2000-01-11	2007-09-13	Greenville Hospital System	Hybrid cells
US20030223935A1 (en) *	2001-03-05	2003-12-04	Gray Brian D.	Fluorescent membrane intercalating probes and methods for their use
AU2001245424B2 (en) *	2000-03-03	2005-08-18	Phanos Technologies, Inc.	Fluorescent membrane intercalating probes and methods for their use
WO2002008454A2 (en) *	2000-07-24	2002-01-31	Genprime, Inc.	Method and device for viable and nonviable prokaryotic and eukaryotic cell quantitation
WO2002012896A1 (en) *	2000-08-08	2002-02-14	Aviva Biosciences Corporation	Methods for manipulating moieties in microfluidic systems
US7309581B2 (en) *	2000-11-01	2007-12-18	Sysmex Corporation	Method of staining, detection and counting bacteria, and a diluent for bacterial stain
US6689391B2 (en)	2001-03-30	2004-02-10	Council Of Scientific & Industrial Research	Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses
US20020159625A1 (en) *	2001-04-02	2002-10-31	Cytoprint, Inc.	Method and apparatus for discovering, identifying and comparing biological activity mechanisms
EP1406492B1 (en) *	2001-06-06	2009-12-30	Perfusion Partners & Associates, Inc.	Centrifuge tube assembly
US6955872B2 (en) *	2003-03-20	2005-10-18	Coulter International Corp.	Dye compositions which provide enhanced differential fluorescence and light scatter characteristics
SI1656455T1 (sl) *	2003-08-13	2012-12-31	Sandoz Ag	Postopek za ÄŤiĹˇÄŤenje rekombinantnih polipeptidov
US7776529B2 (en)	2003-12-05	2010-08-17	Life Technologies Corporation	Methine-substituted cyanine dye compounds
CA2560544C (en)	2004-01-16	2015-05-19	Carnegie Mellon University	Cellular labeling for nuclear magnetic resonance techniques
US10858384B2 (en)	2004-03-22	2020-12-08	Kode Biotech Limited	Synthetic molecule constructs
US7205145B2 (en) *	2004-03-24	2007-04-17	Zefon International, Inc.	Gas-borne matter collection device
US20050266415A1 (en) *	2004-05-28	2005-12-01	Zefon International, Inc.	Method for sampling gas-borne matter
US20060052324A1 (en) *	2004-08-05	2006-03-09	Artandi Steven E	Methods and compositions for cell activation
JP5306811B2 (ja)	2005-05-11	2013-10-02	ライフテクノロジーズコーポレーション	２本鎖ｄｎａへの高い選択性を有する蛍光化学物質及びそれらの使用
AU2005234696B2 (en)	2005-11-18	2012-02-16	Phanos Technologies, Inc.	Fluorescent membrane intercalating probes and methods for their use
WO2008054509A2 (en) *	2006-04-14	2008-05-08	Celsense, Inc.	Methods for assessing cell labeling
WO2007120911A2 (en) *	2006-04-14	2007-10-25	Carnegie Mellon University	Cellular labeling and quantification for nuclear magnetic resonance techniques
ES2264403B1 (es)	2006-06-22	2007-11-01	Grifols S.A.	Medio de suspension de hematies.
US20100203637A1 (en) *	2006-09-06	2010-08-12	Elena Korchagina	Fluorescent cell markers
US7926368B2 (en) *	2006-11-01	2011-04-19	Zefon International, Inc.	Humidity-controlled gas-borne matter collection device
CA2693678C (en) *	2007-07-10	2017-02-14	Carnegie Mellon University	Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
US11266736B2 (en)	2008-04-17	2022-03-08	Vin De Bona Trading Company Pte Ltd	Method of painting micro vesicles
US20110110863A1 (en) *	2008-05-02	2011-05-12	Celsense, Inc.	Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
DE102008040513B4 (de) *	2008-07-17	2010-08-26	BAM Bundesanstalt für Materialforschung und -prüfung	Verwendung einer langwellig emittierenden Cyaninverbindung als NIR-Fluoreszenzstandard und Kit zur Kalibrierung von Photolumineszenzmesssystemen
CN104685346B (zh)	2012-05-02	2018-05-29	查尔斯河实验室公司	细胞捕获系统及其使用
CA2872149C (en)	2012-05-02	2019-03-19	Charles River Laboratories, Inc.	Viability staining method
CN104755931B (zh)	2012-05-02	2016-08-31	查尔斯河实验室公司	用于检测细胞样品中的活细胞的方法
DK2906717T3 (da)	2012-10-11	2019-04-01	Vin De Bona Trading Company Pte Ltd	Fremgangsmåde til maling af mikrovesikler
EP4492037A1 (en) *	2023-07-10	2025-01-15	Sysmex Corporation	Method for detecting platelet aggregation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4343782A (en) *	1978-04-20	1982-08-10	Shapiro Howard M	Cytological assay procedure
US4232121A (en) *	1978-09-25	1980-11-04	Eastman Kodak Company	Process for selecting methine dyes which inhibit cell growth
US4424201A (en) *	1978-11-28	1984-01-03	Rockefeller University	Employment of a mereyanine dye for the detection of malignant leukocytic cells
US4400370A (en) *	1980-03-12	1983-08-23	Lawrence Kass	Metachromatic dye sorption means for differential determination of leukocytes
US4581223A (en) *	1980-03-12	1986-04-08	Lawrence Kass	Individual leukocyte determination by means of differential metachromatic dye sorption
DE3238353A1 (de) *	1982-10-15	1984-04-19	Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	Verfahren zur simultanen quantitativen bestimmung der blutzellen und reagenz hierfuer
US4555396A (en) *	1982-12-22	1985-11-26	Eastman Kodak Company	Use of pyrylium and thiapyrylium compounds as biological stains
JPH06100596B2 (ja) *	1986-09-10	1994-12-12	東亜医用電子株式会社	フロ−サイトメトリ−による白血球の分類方法

1986
- 1986-10-31 US US06/925,192 patent/US4783401A/en not_active Expired - Lifetime
1987
- 1987-10-26 IL IL84278A patent/IL84278A/xx not_active IP Right Cessation
- 1987-10-26 CA CA000550187A patent/CA1311685C/en not_active Expired - Lifetime
- 1987-10-27 PH PH35993A patent/PH23564A/en unknown
- 1987-10-27 IE IE287287A patent/IE69533B1/en not_active IP Right Cessation
- 1987-10-28 AU AU80403/87A patent/AU606894B2/en not_active Ceased
- 1987-10-29 DE DE3750421T patent/DE3750421T2/de not_active Expired - Lifetime
- 1987-10-29 AT AT87309554T patent/ATE110417T1/de not_active IP Right Cessation
- 1987-10-29 PT PT86028A patent/PT86028B/pt not_active IP Right Cessation
- 1987-10-29 EP EP87309554A patent/EP0266194B1/en not_active Expired - Lifetime
- 1987-10-30 JP JP62277256A patent/JPH0737978B2/ja not_active Expired - Lifetime
- 1987-10-30 ZA ZA878157A patent/ZA878157B/xx unknown
- 1987-10-30 CN CN87107216A patent/CN1014547B/zh not_active Expired
- 1987-10-30 KR KR1019870012048A patent/KR970000783B1/ko not_active Expired - Fee Related
- 1987-10-30 DK DK198705703A patent/DK175074B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE110417T1 (de)	1994-09-15
PT86028A (en)	1987-11-01
CN87107216A (zh)	1988-05-11
EP0266194B1 (en)	1994-08-24
IE69533B1 (en)	1996-09-18
EP0266194A2 (en)	1988-05-04
IE872872L (en)	1988-04-30
DE3750421T2 (de)	1995-03-16
DK570387D0 (da)	1987-10-30
US4783401A (en)	1988-11-08
KR880005456A (ko)	1988-06-29
DK175074B1 (da)	2004-05-24
EP0266194A3 (en)	1988-08-03
CA1311685C (en)	1992-12-22
ZA878157B (en)	1988-08-31
JPS63122954A (ja)	1988-05-26
DK570387A (da)	1988-05-01
KR970000783B1 (ko)	1997-01-20
IL84278A (en)	1992-07-15
AU8040387A (en)	1988-05-05
CN1014547B (zh)	1991-10-30
IL84278A0 (en)	1988-03-31
DE3750421D1 (de)	1994-09-29
PH23564A (en)	1989-08-25
AU606894B2 (en)	1991-02-21
PT86028B (pt)	1990-08-31

Legal Events

Date	Code	Title	Description
2004-05-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2004-12-10	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313113
2004-12-20	R360	Written notification for declining of transfer of rights	Free format text: JAPANESE INTERMEDIATE CODE: R360
2005-02-16	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2005-08-16	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2006-05-16	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2007-04-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2007-10-30	EXPY	Cancellation because of completion of term
2008-01-09	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080426 Year of fee payment: 13

Publication	Publication Date	Title
JPH0737978B2 (ja)	1995-04-26	生育可能細胞の標識
JP2872243B2 (ja)	1999-03-17	ｉｎｖｉｖｏ細胞追跡
Horan et al.	1990	Fluorescent cell labeling for in vivo and in vitro cell tracking
US6977156B2 (en)	2005-12-20	Flow cytometry reagent and system
CN103627638B (zh)	2016-03-16	一种用于裂解红细胞的组合物、红细胞裂解试剂及应用
US7195919B2 (en)	2007-03-27	Hematology controls for reticulocytes and nucleated red blood cells
JP2002505441A (ja)	2002-02-19	選択的細胞分析
AU611877B2 (en)	1991-06-27	Differential binding of potential sensitive materials by lymphocytes
US6444471B1 (en)	2002-09-03	Reticulocyte containing complete blood control
Danon et al.	1969	Red cell agglutination kinetics: A method for automatic recording with the fragiligraph
US5830764A (en)	1998-11-03	Methods and reagent compositions for the determination of membrane surface area and sphericity of erythrocytes and reticulocytes for the diagnosis of red blood cell disorders
Lewis et al.	1979	T and B cell analogues from peripheral blood of immune channel catfish, Ictalurus punctatus
US5811303A (en)	1998-09-22	Quantitative buffy coat control composition
WO2018126499A1 (zh)	2018-07-12	网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
US20250003993A1 (en)	2025-01-02	Methods and kits for identifying and quantifying storage-induced microerythrocytes
Stevenson	1948	(1) The Preparation and Value of a Standardised Modification of the Laughlen Test for Syphilis.(2) Investigations on Syphilis Antigen:(a) The Value of Soya Bean Extracts.(b) The Significance of the Diaminomonophosphatide Sphingomyelin
MXPA96004205A (en)	1998-10-23	Direct immunovation by fluorescence conjugated for the activation of plaque
JPH08507370A (ja)	1996-08-06	生存できない細胞の蛍光検出